vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and Onfolio Holdings, Inc (ONFO). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $2.0M, roughly 1.2× Onfolio Holdings, Inc). Onfolio Holdings, Inc runs the higher net margin — -27.0% vs -265.2%, a 238.3% gap on every dollar of revenue. Over the past eight quarters, Onfolio Holdings, Inc's revenue compounded faster (13.0% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Onfolio Holdings Inc. acquires, manages and grows a diversified portfolio of small to medium-sized online businesses, including niche content sites, e-commerce stores, and SaaS tools. It operates primarily in North America and Western Europe, focusing on high-margin, sustainable digital assets with stable revenue streams.
BOLT vs ONFO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $2.0M |
| Net Profit | $-6.6M | $-547.1K |
| Gross Margin | — | 50.0% |
| Operating Margin | -283.4% | -59.1% |
| Net Margin | -265.2% | -27.0% |
| Revenue YoY | — | -20.1% |
| Net Profit YoY | 58.4% | -69.0% |
| EPS (diluted) | $-9.38 | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $2.0M | ||
| Q3 25 | $2.2M | $2.7M | ||
| Q2 25 | $1.8M | $3.1M | ||
| Q1 25 | $1.2M | $2.8M | ||
| Q4 24 | $0 | $2.5M | ||
| Q3 24 | $1.1M | $2.0M | ||
| Q2 24 | $1.3M | $1.7M | ||
| Q1 24 | $5.3M | $1.6M |
| Q4 25 | $-6.6M | $-547.1K | ||
| Q3 25 | $-7.1M | $-700.7K | ||
| Q2 25 | $-8.6M | $-534.4K | ||
| Q1 25 | $-11.0M | $-806.4K | ||
| Q4 24 | $-15.9M | $-323.8K | ||
| Q3 24 | $-15.2M | $-335.6K | ||
| Q2 24 | $-21.2M | $-629.0K | ||
| Q1 24 | $-10.8M | $-477.8K |
| Q4 25 | — | 50.0% | ||
| Q3 25 | — | 64.6% | ||
| Q2 25 | — | 61.6% | ||
| Q1 25 | — | 60.7% | ||
| Q4 24 | — | 53.6% | ||
| Q3 24 | — | 59.9% | ||
| Q2 24 | — | 56.5% | ||
| Q1 24 | — | 63.3% |
| Q4 25 | -283.4% | -59.1% | ||
| Q3 25 | -355.1% | -9.8% | ||
| Q2 25 | -510.5% | -16.1% | ||
| Q1 25 | -991.4% | -27.9% | ||
| Q4 24 | — | -43.9% | ||
| Q3 24 | -1441.1% | -16.5% | ||
| Q2 24 | -1772.3% | -35.1% | ||
| Q1 24 | -324.1% | -28.7% |
| Q4 25 | -265.2% | -27.0% | ||
| Q3 25 | -329.4% | -25.6% | ||
| Q2 25 | -474.6% | -17.0% | ||
| Q1 25 | -903.4% | -28.7% | ||
| Q4 24 | — | -12.8% | ||
| Q3 24 | -1330.1% | -16.7% | ||
| Q2 24 | -1662.4% | -36.4% | ||
| Q1 24 | -205.0% | -30.1% |
| Q4 25 | $-9.38 | $-0.37 | ||
| Q3 25 | $-3.72 | $-0.16 | ||
| Q2 25 | $-4.46 | $0.13 | ||
| Q1 25 | $-0.29 | $-0.18 | ||
| Q4 24 | $-13.73 | $-0.36 | ||
| Q3 24 | $-7.93 | $-0.08 | ||
| Q2 24 | $-11.12 | $0.14 | ||
| Q1 24 | $-0.28 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $2.5M |
| Total Assets | $56.7M | $11.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | — | ||
| Q3 25 | $31.9M | — | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $38.8M | — | ||
| Q4 24 | $47.3M | — | ||
| Q3 24 | $53.8M | — | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | $529.8K |
| Q4 25 | $26.5M | $2.5M | ||
| Q3 25 | $32.1M | $2.2M | ||
| Q2 25 | $38.8M | $3.1M | ||
| Q1 25 | $46.8M | $3.6M | ||
| Q4 24 | $57.2M | $3.3M | ||
| Q3 24 | $72.0M | $3.9M | ||
| Q2 24 | $85.9M | $4.5M | ||
| Q1 24 | $104.2M | $5.2M |
| Q4 25 | $56.7M | $11.4M | ||
| Q3 25 | $65.1M | $8.3M | ||
| Q2 25 | $75.5M | $8.8M | ||
| Q1 25 | $85.9M | $9.4M | ||
| Q4 24 | $99.6M | $9.6M | ||
| Q3 24 | $109.3M | $8.6M | ||
| Q2 24 | $124.2M | $8.9M | ||
| Q1 24 | $142.9M | $8.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-397.3K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-397.3K | ||
| Q3 25 | $-9.7M | $34.2K | ||
| Q2 25 | $-9.6M | $-430.1K | ||
| Q1 25 | $-13.4M | $-145.0K | ||
| Q4 24 | $-14.4M | $-471.6K | ||
| Q3 24 | $-14.0M | $67.0K | ||
| Q2 24 | $-16.1M | $-332.7K | ||
| Q1 24 | $-16.8M | $-431.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOLT
Segment breakdown not available.
ONFO
| B Two B | $1.6M | 81% |
| B Two C | $243.0K | 12% |
| Other | $138.6K | 7% |
